[go: up one dir, main page]

WO2012124311A8 - 新規なフェニルピリジン誘導体及びこれを含有する医薬 - Google Patents

新規なフェニルピリジン誘導体及びこれを含有する医薬 Download PDF

Info

Publication number
WO2012124311A8
WO2012124311A8 PCT/JP2012/001709 JP2012001709W WO2012124311A8 WO 2012124311 A8 WO2012124311 A8 WO 2012124311A8 JP 2012001709 W JP2012001709 W JP 2012001709W WO 2012124311 A8 WO2012124311 A8 WO 2012124311A8
Authority
WO
WIPO (PCT)
Prior art keywords
ring
alkyl group
drug containing
containing same
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2012/001709
Other languages
English (en)
French (fr)
Other versions
WO2012124311A1 (ja
Inventor
三浦　徹
精一 佐藤
肇 山田
潤也 田頭
敏明 渡部
亮平 堰本
石田　理恵
瞳 青木
忠明 扇谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2012227763A priority Critical patent/AU2012227763B2/en
Priority to PH1/2013/501857A priority patent/PH12013501857A1/en
Priority to US14/005,046 priority patent/US9315493B2/en
Priority to PL12757676T priority patent/PL2687523T3/pl
Priority to EA201391314A priority patent/EA026694B1/ru
Priority to CA2830043A priority patent/CA2830043C/en
Priority to RS20160147A priority patent/RS54666B1/sr
Priority to EP12757676.7A priority patent/EP2687523B1/en
Priority to JP2013504561A priority patent/JP5583841B2/ja
Priority to KR1020137026800A priority patent/KR101559307B1/ko
Priority to MX2013010553A priority patent/MX349697B/es
Priority to NZ616158A priority patent/NZ616158B2/en
Priority to BR112013023038A priority patent/BR112013023038B1/pt
Priority to SG2013069398A priority patent/SG193477A1/en
Priority to HK14102384.4A priority patent/HK1189232B/en
Priority to DK12757676.7T priority patent/DK2687523T3/en
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Priority to CN201280006094.2A priority patent/CN103459380B/zh
Priority to ES12757676.7T priority patent/ES2562994T3/es
Publication of WO2012124311A1 publication Critical patent/WO2012124311A1/ja
Publication of WO2012124311A8 publication Critical patent/WO2012124311A8/ja
Anticipated expiration legal-status Critical
Priority to ZA2013/07333A priority patent/ZA201307333B/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

アンジオテンシンＩＩ 受容体拮抗作用及びＰＰＡＲγ活性化作用を併せ持ち、高血圧症、心疾患、動脈硬化症、２型糖尿病等の予防及び／又は治療剤として有用な、下記一般式（Ｉ）で表される化合物、及びそれを含有してなる医薬組成物を提供することを目的とする。一般式（Ｉ）：〔式中、環Ａは、ピリジン環を示し、環Ｂは、テトラゾール環又はオキサジアゾール－５（４Ｈ）－オン環を示し、ＸはＣ－Ｒ５又は窒素原子を示す。Ｒ１は、アルキル基を示し、Ｒ２は、アルキル基又はシクロアルキル基を示し、Ｒ３、Ｒ４、Ｒ５は、それぞれ独立して、水素原子、ハロゲン原子、アルキル基、アルコキシ基等を示す。〕
PCT/JP2012/001709 2011-03-14 2012-03-13 新規なフェニルピリジン誘導体及びこれを含有する医薬 Ceased WO2012124311A1 (ja)

Priority Applications (19)

Application Number Priority Date Filing Date Title
MX2013010553A MX349697B (es) 2011-03-14 2012-03-13 Nuevo derivado de fenilpiridina y farmaco que contiene el mismo.
US14/005,046 US9315493B2 (en) 2011-03-14 2012-03-13 Phenylpyridine derivative and drug containing same
PL12757676T PL2687523T3 (pl) 2011-03-14 2012-03-13 Nowa pochodna fenylopirydyny i lek zawierający ją
EA201391314A EA026694B1 (ru) 2011-03-14 2012-03-13 Фенилпиридиновое производное и содержащее его лекарственное средство
CA2830043A CA2830043C (en) 2011-03-14 2012-03-13 Novel phenylpyridine derivative and drug containing same
PH1/2013/501857A PH12013501857A1 (en) 2011-03-14 2012-03-13 Novel phenylpyridine derivative and drug containing same
EP12757676.7A EP2687523B1 (en) 2011-03-14 2012-03-13 Novel phenylpyridine derivative and drug containing same
JP2013504561A JP5583841B2 (ja) 2011-03-14 2012-03-13 新規なフェニルピリジン誘導体及びこれを含有する医薬
KR1020137026800A KR101559307B1 (ko) 2011-03-14 2012-03-13 신규 페닐피리딘 유도체 및 이를 함유하는 의약
NZ616158A NZ616158B2 (en) 2011-03-14 2012-03-13 Novel phenylpyridine derivative and drug containing same
RS20160147A RS54666B1 (sr) 2011-03-14 2012-03-13 Novi derivat fenilpiridina i lek koji ga sadrži
AU2012227763A AU2012227763B2 (en) 2011-03-14 2012-03-13 Novel phenylpyridine derivative and drug containing same
SG2013069398A SG193477A1 (en) 2011-03-14 2012-03-13 Novel phenylpyridine derivative and drug containing same
HK14102384.4A HK1189232B (en) 2011-03-14 2012-03-13 Novel phenylpyridine derivative and drug containing same
DK12757676.7T DK2687523T3 (en) 2011-03-14 2012-03-13 New phenylpyridinderivat and pharmaceutical containing this
BR112013023038A BR112013023038B1 (pt) 2011-03-14 2012-03-13 composto e uso de um composto
CN201280006094.2A CN103459380B (zh) 2011-03-14 2012-03-13 苯基吡啶衍生物及含有该衍生物的医药
ES12757676.7T ES2562994T3 (es) 2011-03-14 2012-03-13 Nuevo derivado de fenilpiridina y medicamento que contiene el mismo
ZA2013/07333A ZA201307333B (en) 2011-03-14 2013-10-02 Novel phenylpyridine derivative and drug containing same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-055691 2011-03-14
JP2011055691 2011-03-14

Publications (2)

Publication Number Publication Date
WO2012124311A1 WO2012124311A1 (ja) 2012-09-20
WO2012124311A8 true WO2012124311A8 (ja) 2013-05-10

Family

ID=46830402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/001709 Ceased WO2012124311A1 (ja) 2011-03-14 2012-03-13 新規なフェニルピリジン誘導体及びこれを含有する医薬

Country Status (22)

Country Link
US (1) US9315493B2 (ja)
EP (1) EP2687523B1 (ja)
JP (1) JP5583841B2 (ja)
KR (1) KR101559307B1 (ja)
CN (1) CN103459380B (ja)
AU (1) AU2012227763B2 (ja)
BR (1) BR112013023038B1 (ja)
CA (1) CA2830043C (ja)
CY (1) CY1117348T1 (ja)
DK (1) DK2687523T3 (ja)
EA (1) EA026694B1 (ja)
ES (1) ES2562994T3 (ja)
HU (1) HUE028252T2 (ja)
MX (1) MX349697B (ja)
PH (1) PH12013501857A1 (ja)
PL (1) PL2687523T3 (ja)
PT (1) PT2687523E (ja)
RS (1) RS54666B1 (ja)
SG (1) SG193477A1 (ja)
TW (1) TWI525088B (ja)
WO (1) WO2012124311A1 (ja)
ZA (1) ZA201307333B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103690955B (zh) * 2013-12-27 2016-04-20 福州乾正药业有限公司 含有替格瑞洛的药物组合物及其制备方法和药物应用
US20210077491A1 (en) * 2017-12-14 2021-03-18 Kowa Company, Ltd. Pharmaceutical composition
CN115138481B (zh) * 2022-07-06 2024-01-26 中南大学 一种将方铅矿、闪锌矿中的至少一种矿物与辉钼矿浮选分离的药剂和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5331165A (en) * 1976-09-03 1978-03-24 Iseki Kaihatsu Koki Continuous specific gravity meter
JPS5779456A (en) * 1980-11-06 1982-05-18 Fujitsu Ltd Voltage readout system by electron beam
JPS6211845A (ja) * 1985-07-10 1987-01-20 Sharp Corp 複写装置
US5472967A (en) 1991-02-20 1995-12-05 Synthelabo 4-pyrimidinone derivatives their preparation and their application in therapy
JPH06211845A (ja) * 1991-05-16 1994-08-02 Glaxo Group Ltd ベンゾフラン誘導体
CN1079223A (zh) * 1991-05-16 1993-12-08 格拉克索公司 苯并呋喃衍生物
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
US5212177A (en) * 1991-12-16 1993-05-18 E. R. Squibb & Sons, Inc. Indole and benzimidazole-substituted dihydropyrimidine derivatives
JPH07179456A (ja) * 1993-12-21 1995-07-18 Nkk Corp アルキルベンゾフラン誘導体及びアンジオテンシンｉｉ拮抗剤
IT1273790B (it) 1994-02-18 1997-07-10 Guidotti & C Spa Labor Derivati eterociclici diazotati aventi attivita' aii antagonista
ZA200903867B (en) * 2006-11-24 2010-08-25 Takeda Pharmaceutical Heteromonocyclic compound and use thereof
EP2074117A2 (en) * 2006-11-24 2009-07-01 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
CA2671943A1 (en) 2006-12-21 2008-07-17 Pfizer Products Inc. Compounds having both angiotensin ii receptor antagonism and ppary activating activities
WO2008096820A1 (ja) 2007-02-07 2008-08-14 Kyowa Hakko Kirin Co., Ltd. ビフェニル誘導体
JP4866901B2 (ja) 2007-02-07 2012-02-01 協和発酵キリン株式会社 ３環系化合物
EP2151440A4 (en) 2007-05-21 2010-10-20 Takeda Pharmaceutical Heterocyclic compound and use thereof
JPWO2010095462A1 (ja) 2009-02-23 2012-08-23 興和株式会社 新規な３−（５−アルコキシピリミジン−２−イル）ピリミジン−４（３ｈ）−オン構造を有する化合物及びこれを含有する医薬
EP2420501A4 (en) 2009-04-17 2012-08-29 Kowa Co NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4- (3H) -ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME
JP5583681B2 (ja) * 2009-09-29 2014-09-03 興和株式会社 新規なフェニルピリジン誘導体及びこれを含有する医薬

Also Published As

Publication number Publication date
AU2012227763A2 (en) 2013-11-14
JP5583841B2 (ja) 2014-09-03
TWI525088B (zh) 2016-03-11
HUE028252T2 (en) 2016-12-28
EA026694B1 (ru) 2017-05-31
DK2687523T3 (en) 2016-03-14
MX2013010553A (es) 2013-10-28
ZA201307333B (en) 2015-01-28
NZ616158A (en) 2015-07-31
AU2012227763B2 (en) 2016-01-14
US9315493B2 (en) 2016-04-19
BR112013023038A2 (pt) 2016-12-13
CY1117348T1 (el) 2017-04-26
ES2562994T3 (es) 2016-03-09
EP2687523B1 (en) 2016-01-06
EP2687523A4 (en) 2014-11-12
PL2687523T3 (pl) 2016-06-30
PH12013501857A1 (en) 2013-10-14
TW201245180A (en) 2012-11-16
KR20140008431A (ko) 2014-01-21
US20140011823A1 (en) 2014-01-09
BR112013023038B1 (pt) 2019-09-03
HK1189232A1 (en) 2014-05-30
WO2012124311A1 (ja) 2012-09-20
CN103459380B (zh) 2015-07-15
AU2012227763A1 (en) 2013-10-24
PT2687523E (pt) 2016-03-31
AU2012227763A8 (en) 2013-11-21
EA201391314A1 (ru) 2014-02-28
CA2830043A1 (en) 2012-09-20
JPWO2012124311A1 (ja) 2014-07-17
KR101559307B1 (ko) 2015-10-12
EP2687523A1 (en) 2014-01-22
CA2830043C (en) 2018-06-05
CN103459380A (zh) 2013-12-18
SG193477A1 (en) 2013-10-30
RS54666B1 (sr) 2016-08-31
MX349697B (es) 2017-08-09

Similar Documents

Publication Publication Date Title
HK1203497A1 (en) Non-systemic tgr5 agonists
PH12016501822A1 (en) Cyclopropaneamine compound
WO2009107850A3 (en) Fused heterocyclic derivative and use thereof
NO20084129L (no) Pyridin(3,4-B)Pyrazinoner
WO2009001060A3 (en) Use of compounds for preparing anti-tuberculosis agents
EP2597088A4 (en) P2X4 Receptor Antagonists
MY158982A (en) Heterocyclic compound
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
PH12012501162A1 (en) Novel antiplatelet agent
MX2012000414A (es) Derivados piridin-4-ilo.
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
MEP6908A (xx) Piridin -4-ilmetilamida za borbu protiv štetočina
MX2013005535A (es) Compuesto de 3- (amino-aril) -piridina.
TN2010000061A1 (en) Tricyclic bridged cyclopentanedione derivatives as herbicides
WO2008152014A3 (en) 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
MX2013011927A (es) Derivados de glicosido y usos de los mismos para el tratamiento de diabetes.
WO2007002313A3 (en) Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
TW200740434A (en) A prophylactic and/or therapeutic agent for for sleep disorders
PH12015501154A1 (en) 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}-ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist
HK1210162A1 (en) Pyrimidinone derivatives as antimalarial agents
WO2012124311A8 (ja) 新規なフェニルピリジン誘導体及びこれを含有する医薬
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
TN2012000093A1 (en) Therapeutic agent for anxiety disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12757676

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013504561

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2830043

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14005046

Country of ref document: US

Ref document number: MX/A/2013/010553

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1301005110

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: 2012757676

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20137026800

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201391314

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2012227763

Country of ref document: AU

Date of ref document: 20120313

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013023038

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2016/0147

Country of ref document: RS

ENP Entry into the national phase

Ref document number: 112013023038

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130909